#begin document (nw/wsj/00/wsj_0023); part 000
nw/wsj/00/wsj_0023   0    0               F.H.    NNP  (TOP(S(NP(NP*         -    -   -   -     (ORG*   (ARG0*        *   -
nw/wsj/00/wsj_0023   0    1           Faulding    NNP              *         -    -   -   -         *        *        *   -
nw/wsj/00/wsj_0023   0    2                  &     CC              *         -    -   -   -         *        *        *   -
nw/wsj/00/wsj_0023   0    3                Co.    NNP              *)        -    -   -   -         *)       *        *   -
nw/wsj/00/wsj_0023   0    4                  ,      ,              *         -    -   -   -         *        *        *   -
nw/wsj/00/wsj_0023   0    5                 an     DT           (NP*         -    -   -   -         *        *        *   -
nw/wsj/00/wsj_0023   0    6         Australian     JJ              *         -    -   -   -     (NORP)       *        *   -
nw/wsj/00/wsj_0023   0    7    pharmaceuticals    NNS              *         -    -   -   -         *        *        *   -
nw/wsj/00/wsj_0023   0    8            company     NN              *)        -    -   -   -         *        *        *   -
nw/wsj/00/wsj_0023   0    9                  ,      ,              *)        -    -   -   -         *        *)       *   -
nw/wsj/00/wsj_0023   0   10               said    VBD           (VP*        say  01   -   -         *      (V*)       *   -
nw/wsj/00/wsj_0023   0   11                its   PRP$    (SBAR(S(NP*         -    -   -   -         *   (ARG1*   (ARG0*   -
nw/wsj/00/wsj_0023   0   12          Moleculon    NNP          (NML*         -    -   -   -     (ORG*        *        *   -
nw/wsj/00/wsj_0023   0   13               Inc.    NNP              *)        -    -   -   -         *)       *        *   -
nw/wsj/00/wsj_0023   0   14          affiliate     NN              *)        -    -   -   -         *        *        *)  -
nw/wsj/00/wsj_0023   0   15           acquired    VBD           (VP*    acquire  01   -   -         *        *      (V*)  -
nw/wsj/00/wsj_0023   0   16         Kalipharma    NNP           (NP*         -    -   -   -     (ORG*        *   (ARG1*   -
nw/wsj/00/wsj_0023   0   17               Inc.    NNP              *)        -    -   -   -         *)       *        *)  -
nw/wsj/00/wsj_0023   0   18                for     IN           (PP*         -    -   -   -         *        *   (ARG3*   -
nw/wsj/00/wsj_0023   0   19                  $      $        (NP(QP*         -    -   -   -   (MONEY*        *        *   -
nw/wsj/00/wsj_0023   0   20                23      CD              *         -    -   -   -         *        *        *   -
nw/wsj/00/wsj_0023   0   21            million     CD        *)))))))        -    -   -   -         *)       *)       *)  -
nw/wsj/00/wsj_0023   0   22                  .      .             *))        -    -   -   -         *        *        *   -

nw/wsj/00/wsj_0023   0    0         Kalipharma    NNP    (TOP(S(NP*)     -    -   -   -        (ORG)   (ARG1*)           *   -
nw/wsj/00/wsj_0023   0    1                 is    VBZ          (VP*      be  01   -   -           *       (V*)           *   -
nw/wsj/00/wsj_0023   0    2                  a     DT       (NP(NP*      -    -   -   -           *    (ARG2*       (ARG0*   -
nw/wsj/00/wsj_0023   0    3                New    NNP    (ADJP(NML*      -    -   -   -       (GPE*         *            *   -
nw/wsj/00/wsj_0023   0    4             Jersey    NNP             *)     -    -   -   -           *)        *            *   -
nw/wsj/00/wsj_0023   0    5                 -    HYPH             *      -    -   -   -           *         *            *   -
nw/wsj/00/wsj_0023   0    6              based    VBN             *)     -    -   -   -           *         *            *   -
nw/wsj/00/wsj_0023   0    7    pharmaceuticals    NNS             *      -    -   -   -           *         *            *   -
nw/wsj/00/wsj_0023   0    8            concern     NN             *)     -    -   -   -           *         *            *)  -
nw/wsj/00/wsj_0023   0    9               that    WDT   (SBAR(WHNP*)     -    -   -   -           *         *     (R-ARG0*)  -
nw/wsj/00/wsj_0023   0   10              sells    VBZ        (S(VP*    sell  01   -   -           *         *          (V*)  -
nw/wsj/00/wsj_0023   0   11           products    NNS          (NP*)     -    -   -   -           *         *       (ARG1*)  -
nw/wsj/00/wsj_0023   0   12              under     IN          (PP*      -    -   -   -           *         *   (ARGM-MNR*   -
nw/wsj/00/wsj_0023   0   13                the     DT          (NP*      -    -   -   -           *         *            *   -
nw/wsj/00/wsj_0023   0   14            Purepac    NNP             *      -    -   -   -    (PRODUCT)        *            *   -
nw/wsj/00/wsj_0023   0   15              label     NN       *)))))))     -    -   -   -           *         *)           *)  -
nw/wsj/00/wsj_0023   0   16                  .      .            *))     -    -   -   -           *         *            *   -

nw/wsj/00/wsj_0023   0    0      Faulding   NNP    (TOP(S(NP*)        -    -   -   -        (ORG)   (ARG0*)        *         *         *   -
nw/wsj/00/wsj_0023   0    1          said   VBD          (VP*        say  01   -   -           *       (V*)        *         *         *   -
nw/wsj/00/wsj_0023   0    2            it   PRP   (SBAR(S(NP*)        -    -   -   -           *    (ARG1*    (ARG0*)   (ARG0*)   (ARG0*)  -
nw/wsj/00/wsj_0023   0    3          owns   VBZ       (VP(VP*        own  01   -   -           *         *       (V*)        *         *   -
nw/wsj/00/wsj_0023   0    4           33     CD       (NP(NP*         -    -   -   -   (PERCENT*         *    (ARG1*         *         *   -
nw/wsj/00/wsj_0023   0    5             %    NN             *)        -    -   -   -           *)        *         *         *         *   -
nw/wsj/00/wsj_0023   0    6            of    IN          (PP*         -    -   -   -           *         *         *         *         *   -
nw/wsj/00/wsj_0023   0    7     Moleculon   NNP       (NP(NP*         -    -   -   -        (ORG)        *         *         *         *   -
nw/wsj/00/wsj_0023   0    8            's   POS             *)        -    -   -   -           *         *         *         *         *   -
nw/wsj/00/wsj_0023   0    9        voting    NN             *         -    -   -   -           *         *         *         *         *   -
nw/wsj/00/wsj_0023   0   10         stock    NN          *))))        -    -   -   -           *         *         *)        *         *   -
nw/wsj/00/wsj_0023   0   11           and    CC             *         -    -   -   -           *         *         *         *         *   -
nw/wsj/00/wsj_0023   0   12           has   VBZ          (VP*       have  03   -   -           *         *         *       (V*)        *   -
nw/wsj/00/wsj_0023   0   13            an    DT          (NP*         -    -   -   -           *         *         *    (ARG1*         *   -
nw/wsj/00/wsj_0023   0   14     agreement    NN             *         -    -   -   -           *         *         *         *         *   -
nw/wsj/00/wsj_0023   0   15            to    TO        (S(VP*         -    -   -   -           *         *         *         *         *   -
nw/wsj/00/wsj_0023   0   16       acquire    VB          (VP*    acquire  01   -   -           *         *         *         *       (V*)  -
nw/wsj/00/wsj_0023   0   17            an    DT          (NP*         -    -   -   -   (PERCENT*         *         *         *    (ARG1*   -
nw/wsj/00/wsj_0023   0   18    additional    JJ             *         -    -   -   -           *         *         *         *         *   -
nw/wsj/00/wsj_0023   0   19           19     CD             *         -    -   -   -           *         *         *         *         *   -
nw/wsj/00/wsj_0023   0   20             %    NN    *))))))))))        -    -   -   -           *)        *)        *         *)        *)  -
nw/wsj/00/wsj_0023   0   21             .     .            *))        -    -   -   -           *         *         *         *         *   -

nw/wsj/00/wsj_0023   0    0           That     DT  (TOP(S(NP(NP*          -    -   -   -           *        *    (ARG0*         *   -
nw/wsj/00/wsj_0023   0    1          stake     NN              *)         -    -   -   -           *        *         *         *   -
nw/wsj/00/wsj_0023   0    2              ,      ,              *          -    -   -   -           *        *         *         *   -
nw/wsj/00/wsj_0023   0    3       together     RB      (PP(ADVP*)         -    -   -   -           *        *         *         *   -
nw/wsj/00/wsj_0023   0    4           with     IN              *          -    -   -   -           *        *         *         *   -
nw/wsj/00/wsj_0023   0    5            its   PRP$           (NP*          -    -   -   -           *        *         *         *   -
nw/wsj/00/wsj_0023   0    6    convertible     JJ              *          -    -   -   -           *        *         *         *   -
nw/wsj/00/wsj_0023   0    7      preferred    VBN          (NML*      prefer  01   -   -           *      (V*)        *         *   -
nw/wsj/00/wsj_0023   0    8          stock     NN              *)         -    -   -   -           *   (ARG1*         *         *   -
nw/wsj/00/wsj_0023   0    9       holdings    NNS             *))         -    -   -   -           *        *)        *         *   -
nw/wsj/00/wsj_0023   0   10              ,      ,              *)         -    -   -   -           *        *         *)        *   -
nw/wsj/00/wsj_0023   0   11          gives    VBZ           (VP*        give  01   -   -           *        *       (V*)        *   -
nw/wsj/00/wsj_0023   0   12       Faulding    NNP           (NP*)         -    -   -   -        (ORG)       *    (ARG2*)   (ARG0*)  -
nw/wsj/00/wsj_0023   0   13            the     DT           (NP*          -    -   -   -           *        *    (ARG1*         *   -
nw/wsj/00/wsj_0023   0   14          right     NN              *          -    -   -   -           *        *         *         *   -
nw/wsj/00/wsj_0023   0   15             to     TO         (S(VP*          -    -   -   -           *        *         *         *   -
nw/wsj/00/wsj_0023   0   16       increase     VB           (VP*    increase  01   1   -           *        *         *       (V*)  -
nw/wsj/00/wsj_0023   0   17            its   PRP$           (NP*          -    -   -   -           *        *         *    (ARG1*   -
nw/wsj/00/wsj_0023   0   18       interest     NN              *)         -    -   -   -           *        *         *         *)  -
nw/wsj/00/wsj_0023   0   19             to     IN           (PP*          -    -   -   -           *        *         *    (ARG4*   -
nw/wsj/00/wsj_0023   0   20            70      CD        (NP(NP*          -    -   -   -   (PERCENT*        *         *         *   -
nw/wsj/00/wsj_0023   0   21              %     NN              *)         -    -   -   -           *)       *         *         *   -
nw/wsj/00/wsj_0023   0   22             of     IN           (PP*          -    -   -   -           *        *         *         *   -
nw/wsj/00/wsj_0023   0   23      Moleculon    NNP        (NP(NP*          -    -   -   -        (ORG)       *         *         *   -
nw/wsj/00/wsj_0023   0   24             's    POS              *)         -    -   -   -           *        *         *         *   -
nw/wsj/00/wsj_0023   0   25         voting     NN              *          -    -   -   -           *        *         *         *   -
nw/wsj/00/wsj_0023   0   26          stock     NN      *)))))))))         -    -   -   -           *        *         *)        *)  -
nw/wsj/00/wsj_0023   0   27              .      .             *))         -    -   -   -           *        *         *         *   -

#end document
